VIDEX EC
LOE ApproachingNDAORALCAPSULE, DELAYED REL PELLETSPriority Review
Approved
Oct 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIDEX EC (didanosine) is an oral nucleoside reverse transcriptase inhibitor (NRTI) approved in 2000 for HIV infection treatment. Administered as delayed-release pellet capsules, it works by inhibiting HIV-1 reverse transcriptase to reduce viral replication in patients with established HIV disease.
LOE Approaching
Declining
Product approaching loss of exclusivity with low competitive pressure (30), indicating potential team contraction and shift toward generic transition or portfolio reallocation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VIDEX EC offers limited growth trajectory given LOE-approaching status and minimal job posting activity (0 linked roles). Career opportunities are primarily in managed care negotiations, generic transition planning, or portfolio rationalization rather than market expansion or field launch activities.
Brand ManagerField Sales Representative
Worked on VIDEX EC at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.